Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
236 Clinical Updates found
An illustration depicts multiple myeloma, a type of blood cancer. The image shows a red background with various blood cells floating within it.
MSK ASH 2024 Research Roundup: Practice-Changing Advances in Leukemia, Lymphoma, and Multiple Myeloma

Memorial Sloan Kettering Cancer Center (MSK) researchers presented results of their latest research at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego from December 7 to 10, 2024.
MSK Kids: The First Hospital in New York City Offering Gene Therapy for Sickle Cell Disease and Beta Thalassemia
MSK Kids: First in New York City Offering Gene Therapy for Sickle Cell Disease and Beta Thalassemia

A Q&A with Jaap-Jan Boelens, MD, PhD, Chief of the Pediatric Transplant and Cellular Therapy Service at MSK.
A Decision-Making Model for Selecting Surgery or Radiotherapy for Early-Stage Lung Cancer
A Decision-Making Model for Selecting Surgery or Radiotherapy for Early-Stage Lung Cancer

A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the Annals of Surgery,([i]) is the first to identify a comprehensive list of clinical factors significantly associated with referring patients with stage 1 NSCLC to SBRT.
Tumor Hypoxia: A Clinical Biomarker of Distant Metastasis Risk after Chemoradiotherapy for Head and Neck Cancer
Tumor Hypoxia: A Clinical Biomarker of Distant Metastasis Risk after Chemoradiotherapy for Head and Neck Cancer

Tumor hypoxia on 18F-fluoromisonidazole (FMISO) positron emission tomography (PET) may serve as a reliable clinical biomarker of distant metastasis risk for patients with head and neck squamous cell carcinoma (HNSCC) after chemoradiotherapy (CRT), according to a study by MSK researchers.
Expanding Active Surveillance Eligibility for Patients with Intermediate-Risk Prostate Cancer
Expanding Active Surveillance Eligibility for Patients with Intermediate-Risk Prostate Cancer

Evidence from a recent study, led by MSK urologic surgeon, Behfar Ehdaie, MD, MPH, indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required.
MSK Research Team Identifies New, Rare Type of Small Cell Lung Cancer
MSK Research Team Identifies New, Rare Type of Small Cell Lung Cancer

A Memorial Sloan Kettering Cancer Center (MSK) research team has identified a new, rare type of small cell lung cancer (SCLC) — dubbed “atypical SCLC” — that primarily affects younger people who have never smoked.
Physician working in laboratory
MSK Researchers Report Exciting Cancer Research Advances at ESMO Congress 2024

Memorial Sloan Kettering Cancer Center (MSK) experts shared the results from cutting-edge advances in cancer research at the European Society of Medical Oncology (ESMO) Congress 2024, held in Barcelona, Spain, September 13 to 17, 2024.
Select Patients with Seminoma Metastatic to the Retroperitoneum May Safely Avoid Chemotherapy and Radiation with primary RPLND
Select Patients with Seminoma Metastatic to the Retroperitoneum May Safely Avoid Chemotherapy and Radiation with Primary RPLND

A Q&A with MSK Urologic Surgeon Richard Matulewicz, MD, MSCI, MS.
A New Endpoint for Accelerated Approvals in Multiple Myeloma
A New Endpoint for Accelerated Approvals in Multiple Myeloma

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval of new drugs and new indications in multiple myeloma clinical trials.
The Main Cause of Non-Relapse Mortality after CAR T Cell Therapy is Not What You Think
Post-Transplantation Prophylaxis Resulted in Similar Outcomes for Mismatched and Matched Donor Stem Cell Transplants

According to a large retrospective study co-led by Memorial Sloan Kettering Cancer Center and published in the Journal of Clinical Oncology, PTCy is an acceptable alternative to CNI-based prophylaxis in MUD HCT recipients and superior for MMUD HCT. These results will help improve minority donor participation in the NMDP registry.